EQT

Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.

FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company specializes in developing first-in-class therapeutic compounds for cancer treatment by targeting key molecular mechanisms related to DNA replication stress. This innovative approach aims to create targeted anticancer drugs that address critical aspects of cancer biology. As a privately-held entity, FoRx Therapeutics is committed to advancing its research and development efforts in the oncology space.

SHL Group, based in Zug, Switzerland, specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto injectors, pen injectors, and inhaler systems. Founded in 1989, the company provides comprehensive services, such as final assembly, labeling, and packaging, for pharmaceutical and biotech firms globally. SHL Group prioritizes compliance with strict regulations and upholds high-quality standards in its operations. The company emphasizes the importance of talent development and collaboration among its employees to enhance productivity and customer satisfaction. By focusing on these core principles, SHL Group aims to deliver superior business outcomes while maintaining professionalism in all aspects of its work.

Galderma S.A. is a global company specializing in the manufacture and distribution of medical, consumer skin health, and dermatology products. Founded in 1981 and headquartered in Lausanne, Switzerland, Galderma offers a wide range of solutions including prescription medicines, medical aesthetics, and skincare products. Its extensive product portfolio addresses various dermatological conditions such as acne, rosacea, psoriasis, and skin cancer, with well-known brands like Epiduo®, Differin®, and Restylane®. The company operates through a network of 33 wholly-owned affiliates and distributors in approximately 80 countries, employing around 6,600 people. Galderma emphasizes innovation in meeting the dermatological needs of individuals and healthcare professionals, with research and development, and manufacturing sites located across multiple regions including Europe, Asia-Pacific, and the Americas.

Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.

Inspired is a co-educational, non-denominational independent school group based in London, with additional locations in Johannesburg, South Africa. The organization operates a network of private schools across Europe, Australia, and Africa, including sites in Berkshire, Switzerland, Sydney, and several cities in South Africa such as Cape Town and Pretoria. Catering to students aged 1 to 18, Inspired aims to foster an environment that encourages academic achievement and personal growth. The school group emphasizes a progressive approach to education, reevaluating traditional teaching methods and curriculums to provide a more dynamic and relevant learning experience that reflects contemporary attitudes and prepares students for future challenges.

Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Open Systems AG is an IT security specialist headquartered in Zurich, Switzerland, with additional offices in Sydney and New York. Founded in 1990, the company provides a range of services focused on network security, application delivery, identity management, and global connectivity. Its offerings include distributed and enterprise firewalls, WAN encryption, network security monitoring, intrusion prevention, and Wi-Fi security. Open Systems also specializes in web application firewalls, email gateways, and application performance management. In the realm of identity management, it offers federated identity management and strong authentication solutions. Furthermore, the company helps enterprises secure their cloud operations through 24/7 expertise and an intelligent platform designed to predict, prevent, detect, and respond to cyber threats. Open Systems serves various sectors, including government, finance, healthcare, and retail, providing tailored solutions to meet their unique security needs.

CHEP specializes in enhancing supply chain efficiency through its innovative capabilities and insights, helping customers to increase sales, reduce costs, and promote sustainability. CHEP Aerospace Solutions, based in Zurich, Switzerland, offers asset management and repair services for unit load devices (ULDs), galley carts, and ground support equipment. This division enables airlines to concentrate on their core activities of passenger and cargo transport while benefiting from significant cost savings and operational improvements. CHEP Aerospace Solutions manages the world’s largest independent fleet of ULDs and operates the most extensive global network for the maintenance and repair of containers, pallets, and inflight food service equipment, providing tailored outsourcing solutions for over 80 airlines worldwide.

Unilode Aviation Solutions, formerly known as CHEP Aerospace Solutions, is a prominent provider of unit load device (ULD) pooling, management, maintenance, and repair services tailored for the aviation sector. The company operates the world's largest independent fleet of approximately 100,000 ULDs and maintains an extensive global network dedicated to the maintenance and repair of ULDs and galley carts. By offering lightweight pooling options that include aluminum and lightweight containers, as well as standard and heavy-duty pallets, Unilode enables airlines and cargo carriers to reduce costs through outsourced ULD services. This approach allows clients to efficiently manage their ULD and galley cart fleets, enhancing operational effectiveness in the transportation of cargo and baggage on both passenger and cargo aircraft.

Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

Kuoni Group is a global leisure and destination management travel organization based in Zurich, Switzerland, with operations across Europe, Asia, Africa, Australia, and North America. Founded in 1906, it serves consumers through both online and offline channels. The company's core activities include Global Travel Distribution, which provides travel companies with access to hotel accommodations and destination services, and Global Travel Services, which coordinates a range of destination-related offerings, including tours and event management. Kuoni Group is a leader in the group travel market, handling around 50,000 leisure tours annually. Additionally, it operates VFS Global, a premier visa services provider for 48 governments, with a significant presence in the Asia/Pacific region. In 2015, Kuoni Group reported a turnover of CHF 3.35 billion and employed approximately 8,000 people, with a strong focus on sustainable growth in emerging markets.

Kuoni Reisen Holding AG, based in Switzerland, operates primarily in the travel industry, serving both travel companies and government entities. The company focuses on three main areas: Global Travel Distribution (GTD), which offers hotel accommodation and destination services; Global Travel Services (GTS), which coordinates comprehensive destination management services including accommodation, transportation, tours, and event management; and Visa Facilitation Services (VFS), which manages visa outsourcing through various application centers globally. Additionally, Kuoni Destination Management provides event solutions for virtual, hybrid, and live events, covering aspects such as entertainment, technology, logistics, and creative direction. This diverse portfolio positions Kuoni Reisen Holding as a significant player in the travel and event management sectors.

Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.

Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Evidensia Djursjukvård AB owns and operates veterinary hospitals and clinics in Sweden, Norway, Denmark, Finland, Holland, Germany, and Switzerland.

Sportradar AG is a prominent provider of sports-related live data and digital content services, catering to media companies, bookmakers, sports federations, and regulatory authorities globally. Established in 2001 and headquartered in Sankt Gallen, Switzerland, Sportradar focuses on the collection, processing, and commercialization of sports data. The company monitors the global betting market for unusual patterns and collaborates with sports federations and law enforcement to combat betting-related manipulations, including match-fixing. Sportradar offers a comprehensive range of products and services, including data collection, managed trading, live streaming, and various solutions for bookmakers, such as odds compilation and live data visualization. The company maintains a strong presence worldwide, with offices in major cities across Europe, Asia, and North America, and partners with leading international sports organizations to ensure the integrity and security of sports data.

Swiss Smile Holding AG operates a network of dental competence centers, providing a comprehensive range of dental services including aesthetic dentistry, bleaching, implantology, orthodontics, oral surgery, endodontics, pediatric dentistry, periodontology, and professional teeth cleaning. Established in 2002, the company caters to both local and international patients, with centers located in various Swiss cities such as Zurich, Baden, St. Moritz, Suhr, and Winterthur, as well as international locations including Bengaluru, Moscow, and London. Swiss Smile also offers dental hygiene products such as whitening toothpastes, toothbrushes, and interdental brushes. Additionally, the company emphasizes preventive care and education, offering dentistry classes in schools to promote oral health awareness.

Sportradar AG is a prominent provider of sports-related live data and digital content services, catering to media companies, bookmakers, sports federations, and regulatory authorities globally. Established in 2001 and headquartered in Sankt Gallen, Switzerland, Sportradar focuses on the collection, processing, and commercialization of sports data. The company monitors the global betting market for unusual patterns and collaborates with sports federations and law enforcement to combat betting-related manipulations, including match-fixing. Sportradar offers a comprehensive range of products and services, including data collection, managed trading, live streaming, and various solutions for bookmakers, such as odds compilation and live data visualization. The company maintains a strong presence worldwide, with offices in major cities across Europe, Asia, and North America, and partners with leading international sports organizations to ensure the integrity and security of sports data.

Atos Medical was founded in 1986 and today has a vast international network with subsidiaries in the USA, UK, Germany, Spain, Netherlands, Belgium, Sweden and Switzerland and also exclusive distributors serving about 60 countries. The head office is situated in Sweden, where a state-of-the-art clean room and laboratory make it possible to perform all tests required for successful R&D.

Leading the field of high-quality, sealing and flow control technology, SFC KOENIG® manufacturers and develops a wide range of products and highly reliable solutions, both standard and customized, for an unrivalled means of delivering precise sealing, flow control and regulation. SFC KOENIG solutions meet the highest safety and environmental requirements, achieving increased system reliability and efficiency while preventing damage to components. They design and manufacture their sealing and flow control solutions to reduce waste in the supply chain and lower lifecycle costs, producing parts with lower total production costs.

Verisure Sverige is a prominent provider of monitored security solutions tailored for residential and small business customers. Based in Malmö, Sweden, the company serves approximately 2 million clients across 14 countries in Europe and Latin America. Established in 1988, Verisure operates primarily under the brand name Verisure, while it is known as Securitas Direct in Spain and Portugal. The company is recognized for its commitment to delivering peace of mind and protection, with a new security system being installed globally every 30 seconds. As a subsidiary of Verisure Midholding AB, Verisure Sverige continues to expand its reach and enhance its service offerings in the security sector.

Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly

PharmaZell GmbH develops and produces generic active pharmaceutical ingredients (API), controlled substances, and amino acids. The company also offers custom synthesis and finished dosage form development projects. It serves the pharmaceutical industry worldwide. The company was founded in 1947 and is based in Raubling, Germany with production plants in Liestal, Switzerland; Gropello Cairoli, Italy; and Chennai and Vizag, India. It also has a sales branch in Cleveland, Ohio. PharmaZell GmbH is a prior subsidiary of Zellbios S.A.

Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

CBR Fashion Holding AG is a German apparel wholesaler focused on women's fashion, targeting customers aged 25 to 50. The company offers a diverse range of products, including pants, denim, shirts, knitwear, and outerwear, marketed primarily under the Street One and Cecil brand names. CBR operates a dual business model that includes both wholesale distribution and retail, with a presence in 64 retail stores and 7 outlet stores in Germany, as well as additional outlets in Switzerland and Italy. The company's strategy emphasizes rapid turnover and responsiveness, producing twelve collections annually for each brand. Founded in 1980 and based in Celle, Germany, CBR Fashion Holding AG was formerly known as CBR Fashion Holding GmbH until its name change in June 2015.

4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.

4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.